Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.49 |
| ▸ | NPY1R | P25929 | 6/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464056 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30449937 | 0.95 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL38660264 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL31453827 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29420164 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30152128 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29461968 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RFNTA | |
| SCHEMBL17887897 | 0.93 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL17887995 | 0.93 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30676227 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | NPY4R 708/4885NPY1R 438/4885NPY2R 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.